ORIGINAL RESEARCH PAPER
Volume - 10 | Issue - 07 | July - 2021 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

HIGHLIGHTS OF COVID VACCINE ERA'S IN LOW ASSETNATIONS.

Pharmacy

Bhavesh Patel* Assistant Professor PG Studies in Chemistry and Pharmacy Rani Durgavati University, Jabalpur MP 482001. *Corresponding Author

Pradeep Golani Associate Professor, Gyan Ganga Institute of Technology and Sciences, Jabalpur.

Sanjay A. Nagdev Assistant professor, Department of Pharmaceutical Analysis, Shri. Prakash Chand Jain College of Pharmacy & Research, Palaskheda (Bk.), Jamner Maharashtra.

Miss. Himani Jaisinghani Assistant professor Department of pharmaceutics Indore institute of pharmacy, Indore.

Dr RP Mishra Head of Department PG Studies in Chemistry and Pharmacy Rani Durgavati University, Jabalpur MP 482001.

ABSTRACT

In the war against COVID-19, vaccination resistance is an immediate challenge because the achievement of vaccine coverage relies on the potency of the vaccine itself and the readiness of the population to tolerate it[1]. Over time, all vaccinations lose efficacy and the rate of efficiency loss depends on temperature as well[2].This research provides an analysis of numerous factors and the potential risk of unwellness and protection of vaccines, such as their efficacy, stability.Both of these examples have led to the classification of vaccines, mutating new COVID strain, challenges as regulatory demand with the organisation and the possibility of precession drugs within low-resource countries where operation distinction by HPLC with the spectrographic analyses.

KEYWORDS

INTRODUCTION

Once vaccination starts, as a result of vaccine adoption, it is important to appropriately stress the potential decrease of new COVID-19 cases instead of being treated as a reduced risk, which could lessen the anticipated demand for vaccination [3]. Multi-factor responses and, potentially, intervention can influence the functional risk of disease and vaccine safety concerns, and even some questions.In order to inspire a constructive, collaborative pandemic reaction, the influence of words and framing seen in this study tends to focus attention on strategy formulation. Continuous changes to campaign material and reactions to monitoring should not be neglected. When vaccination begins, instead of being seen as a reduced risk, it is important to accurately stress the potential decrease in new COVID-19 cases as a result of vaccine adoption, which could minimise the potential need for vaccines[3]. The complexities of introducing these new formulas, as well as the possible advantages and rewards of withdrawing vaccines from the cold chain, are addressed. For safety, COVID vaccines given by injection are recommended by the WHO[5].

The sensitivity of thermal deterioration injections, however, has prompted WHO and UNICEF to prescribe cold-chain storage of all vaccine materials. Nonetheless, some injectable goods supplied to the global market are marked for storage at around 25 ° C, and with a shorter shelf-life compared to products marked for cooling[6]. Differences in the criteria for labelling storage will lead to uncertainties among stakeholders about the relative stability of COVID vaccine products and specifically if degradation is more resistant to ~25 ° C products[7]. Such uncertainty can theoretically impact procurement, delivery, storage and utilisation of COVID vaccine policies in resource-poor environments.

Stability of Vaccines Frequently Used

The heft of the present usually utilized vaccines have a timeframe of realistic usability of two years or more when put away at 2-8°C. Immunization affectability to trips outside of this reach, then again, differs incredibly [8]. Likewise, lyophilized microbes are typically steady just barely before to reconstitution. In the wake of being reconstituted, the viability of live-attenuated vaccines including those for measles and yellow fever would rapidly crumble [9]. Reconstituted immunizations should be kept cold, and any excess multi-portion vial vaccines ought to be discarded inside 6 hours, as indicated by WHO proposals [10] because of the destabilization of reconstituted vaccine and they have no preservatives to withstand against unwanted bacterial growth [11]

In the cold chain management of temperature dependent stability issue

A cold chain for vaccine stockpiling and circulation can be underlying any locale, as per experience [12]. Despite this, the initiative is a big task, implementation is difficult, and current programs are constantly strained by the influx of new vaccinations into low- and middle-income nations [13].

It's likewise clear that, in the midst of the best expectations, cold chain don't frequently proceed as they ought to, for various causes, including gravely oversaw or old refrigeration gadgets, a disappointment of force or a deficiency of fuel to work gear, deficient consistence with cold-chain methodology, insufficient oversight, and an absence of information on the risks of freezing immunizations.

Freezing vaccine exposure

Cold-chain management have basic aim on shielding vaccines from unnecessary heat, resulting in inappropriate freezing being the most serious threat to vaccine quality [14].

When the amount of costly freeze-sensitive vaccinations used in immunisation programmes grows, this is an extremely significant issue; freeze-sensitive vaccines are projected to account for over 31% of the US$439 million expended on all vaccines by the UN Children's Fund in 2005[15].

Another efficient investigation of revealed cold-chain examines showed that freezing temperaturesof all vaccine supplies tracked in developed countries were experienced during transport (35.3 percent) or storage (21.9 percent)[16].

Studies that examined cold-chain conditions all the way to health clinics from national or regional retailers showed that 75-100 percent of the shipments were subjected to freezing conditions during the delivery process at least once[17].

With more than 170 separate vaccines in trials, the battle against COVID vaccines has advanced at record pace with the four different forms of vaccines operating here[21]. But how do they vary from each other and how do they shield us from disease.

Types of Corona virus vaccine approaches

Scientists are casting a wide net to see what best against the novel corona virus as shown in Table 1

Table 1Approaches of different types of Corona virus vaccine

Types of Vaccines	DNA and RNA	Live attenuated	Inactivated	Subunit	Viral Vector
					
How it works	It uses DNA or RNA to reach the immune system to target key viral proteins	It is a weakened version of the actual virus.	It uses the whole virus after it has been killed with chemicals or by heating	It works by using a piece of a virus's surface to guide the immune system's attention to a specific target.	It takes the harmless virus and uses to deliver viral genes to build immunity.
Advantages	Easy and quick to design	Stimulates a robust immune response without causing serious disease	Safe because the virus is already dead and is easy to make	Focuses on the most important part of the virus for protection	Live viruses tend to elicit stronger immune responses that dead viruses.
Disadvantage	Never been done before. There are no licensed DNA or RNA vaccines currently in use.	May not be safe for those with compromised immune systems	Not as effective as a live virus. Some previous inactivated vaccines have made the defence worse, safety for the novel corona virus needs to be shown in clinical trials	May not stimulates strong response other chemical needs to be added to boost the long-term immunity	Important to pick a viral vector that is truly safe. An immune response to viral vector may make the vaccine less effective
Existing Examples	None	Measles Mumps Rubella (MMR), chicken pox	Polio	Pertussis, Hepatitis B, Human Papilomavirus (HPV)	EBOLA, Veterinary medicines
Group testing this approach for COVID-19	• Moderna (RNA) • Inovio (DNA)	• Codagenix • Indian immunological Ltd	• Sinovac • Sinopharm	• Novavax • Adaptvac	• University of Oxford & Astra Zeneca • CanSino biologics • Jhonsons&Jhonson

With the severity of the latest pandemic, it's no wonder that scientists around the world are rushing to produce a SARS-COV-2 vaccine as well as separation-based analytic evaluation methods to monitor the progress of the cold chain COVID-19 vaccine [18]. There are four main types of vaccine candidates being investigated, but they all use chromatography and mass spectrometry techniques to characterize them [19]. In this article, we'll look at how chromatographic separations have helped researchers analyze vaccines from each vaccine class as mentioned in Table 2.

Table 2 Different Chromatographic methods used based on type of vaccine.

S.No	Vaccine based on	Examples of vaccines	Assumption	Chromatographic Method applied
1	Viral	Measles and polio	Take reduced, or attenuated, versions (weakened viruses), which leads to relocation of immunity in the individual. That acts as an activated version of the virus for a later date.	The utilization of size exclusion to isolate unblemished viral particles from deteriorated capsid proteins and to additionally filter the substance utilizing ion exchange is portrayed in a paper by Shin et al [23]
2.	Viral Vector	Ebola	They are either replicable or non-replicable. To make proteins from some other microbe to create resistance, an infection is utilized as a vector and hereditarily adjusted [24].	A type of anion exchange was utilized to assess total and void AAV6 capsids by Wang et al [25]. Emily C. Hartman of the University of California [26] was stated that the utilization of size exclusion for quantitative characterization of all single amino acid variants of a viral capsid-based drug delivery vehicle.
3.	DNA / RNA material	Albeit this methodology isn't utilized for any current human-authorized, more than 20 examinations bunches are chipping away at immunizations in this category.	Genetic content from the microorganism that codes for a protein that triggers a resistant reaction is utilized in this methodology [27].	A University of Canberra group covered various methods for decontaminating DNA plasmids for immunizations, from affinity to hydrophobic, in an investigation of purification strategies for DNA vaccines [28]. The N-glycan examples of the Chikungunya infection glycoprotein, near the turn out needed for the SARS-CoV-2 spike glycoprotein were portrayed by one more group drove by Catherine Lancaster [29]. To guarantee the greatest level of reproducibility and speed for additional work, discharge glycan packs are presently accessible.
4	Protein	Hepatitis B vaccine, human papillomavirus	It relies upon viral protein subunits or disease like particles which act by imbuing proteins directly straightforwardly into the circulation system [30]. This aides the muscle, as opposed to the whole infection, to perceive and mount an invulnerable reaction to the protein.	Santana et al. are exhibiting the utilization of size exclusion as a technique for protein-based vaccine, utilizing BioSec-3 innovation to survey the measure of dynamic kind of novel hemagglutinin (HA) utilized in flu antibodies [31].

With ethnic, social, and partisan distinctions, decreasing vaccine approval (from >70% in March to October) was observed. Popular factors included perceived harm, questions about vaccine safety and efficacy, doctor's advice, and inoculation background[32]. The effect of regional rates of infection, ethnicity and personal experience with COVID-19 was inconclusive[33]. Special COVID-19 variables included the orientation of political parties, concerns regarding the expedited phase of development/approval, and potential political intervention[34][35].Many responsive participants wanted to wait before others took the vaccine; mandates could increase the wording of the survey's opposition and response alternatives showed an effect on responses. Communication campaigns focused on accountability and rebuilding confidence in health authorities are required urgently to achieve herd immunity (Cheryl Lin etal)[34].

Inconveniences related with making COVID-19 Vaccines Manufactures and Supply chain

1. Immunogenicity and quality: Main reasons are new excipients because of thatkeen observation based investigation with considering safety as need is required.
2. Novel process and machinery: It should meet the cGMP norms; In special cases scrutiny of regulatory is required.
3. Infants as a Target population: This group required the very stringent safety because of extremely low resistance of adverse effect due novel concept like formulation, with required post marketing survey.
4. Formulation based development : It is difficult due to lack of predictive preclinical models and potency assay, it may increase the clinical testing required for endorsement
5. Reformulation product: Clinical assay with clinical endpoints and biomarkers for some infection is difficult to approved, it take longer preliminaries with clinical with non-inferiority focusing on immunogenicity as per norms of quality standard.
6. In future we will come across with combination therapy of reformulated vaccines: This might have an issue with mix-up due to interface distinctively segments and with excipients. This type of therapy required compliance of testing of non inferiority clinical investigations before it release to market
7. Equitable and global distribution: Cost engaged with the way toward assembling to its endorsement of reformulated COVID-19 vaccine will be gigantic and not feasible for public business sectors. It get hard to legitimize with business polices to go for interest in this interaction of improved detailing. With the improvement of expected vaccine for Covid-19 advancing rapidly, we need to put now in foundation for dispersing an immunization around the world on an impartial premise when it is demonstrated protected and powerful. An opportunity to get ready for worldwide circulating a Covid-19 immunization in a manner that is successful and evenhanded is currently. It will have a drawn out result by assisting with forestalling future pandemics, which researchers anticipate will be more normal as the world's environment warms.
8. Measure the stable vaccine: Due to instability of vaccines has churns the brian for economist and health worker to have seen observation on thermo stability related issue with its advancement cost.
9. Intellectual property vaccine manufacturer:Nations generally desire to get the secured advancement advantages of Covid-19 immunization makers. Taking off interest for the Covid-19 immunization and limited stock have countries by and large looking for ways to deal with fast track vaccinating their occupants. Various countries have gone to the World Health Organization referencing obligatory allowing of Covid-19 immunization licenses from drug producers. A compulsory grant suspends the overwhelming plan of action effect of a patent holder to convey and supply the thing. To guarantee that adjustment advances are promptly accessible and don't hazard the reasonableness of public-area immunizations, the proprietors of such innovations should be persuaded of public-area wellbeing needs. Associations dealing with benefit of the interests of the public area ought to build up agreement measures for the public area to ensure Intellectual property; campaigning on both the issue and the arrangement might be needed to proceed.

Diversity of technology platforms:

As of now, neither of these stages are the reason for endorsed vaccines, yet experience in fields like oncology empowers designers to exploit the prospects offered by cutting edge approaches for sped up improvement and conveyance speed[40]. All things considered, these likely programs are better custom-made to explicit subgroups of the populace (like the old, youngsters, pregnant ladies or immunocompromised patients)[41]

Taking into account the different approaches in Table 1, the novel DNA or mRNA-based platforms provide great versatility in terms of antigen modulation and speed ability[42]. Indeed, only 2 months after sequence discovery, Moderna began clinical trials of its mRNA-based mRNA-1273 vaccine[43]. Viral vector-based vaccines have a serious level of protein articulation and long-term stability, with robust immune responses being triggered[44]. Finally, vaccines dependent on recombinant proteins are now approved for other diseases, so these candidates could take advantage of current large-scale manufacturing capacities[45].

Adjuvants may increase immunogenicity for certain platforms and render lower doses feasible, thereby encouraging more individuals to be vaccinated without sacrificing safety. To date, at least 10 developers have indicated intentions to create COVID-19 adjuvant vaccines, and developers of vaccines, including GlaxoSmithKline, Seqirus and Dynavax, have focused on making accessible authorized excipient (AS03, MF59 and CpG1018, respectively) for use with other recently created COVID-19 vaccines.

There is little general awareness on the particular SARS-CoV-2 antigen(s) used in the production of vaccines. The majority of candidates for which information is available seek to trigger viral spike (S) protein neutralising antibodies to prevent absorption through the human ACE2 receptor[46]. It is questionable, in any case, how the different sorts and additionally varieties of the S protein utilized in the different applicants are connected to one another or to the genomic the study of disease transmission of the infection. Involvement in the creation of SARS immunizations recommends the opportunities for the effect of numerous antigens on invulnerable improvement, which involves debate and might be critical to the advancement of vaccines[47].

Emergence of Mutation in corona virus

The corona virus (SARS-CoV-2) like all other viruses has a piece of genetic code which contains all the information the virus needs to survive and reproduce[48]. The mutations rarely been affecting the viral fitness and most of the time not affect the clinical outcomes, however, the detailed effects to be fully determined. RNA is a single stranded version of DNA. Three bases in a row provide the blueprint for bigger molecules known as amino acids. Once the virus infects a person's cells such as human lung cell it reproduces by forcing the human cell to read its RNA and make more viruses[49]. These replicas are exactly same because of the same RNA, but sometimes the cells can `misread` the genetic code resulted an error[50]. This is where the mutation occurs. Other causes of mutations are interactions with other viruses infecting the same cell and the charges induced by the host`s or a person`s own immune system. This happens on the spike protein which ties to the ACE2 receptor, allowing the virus to infect the cell[51].

Changes in virus variants

In all viruses, including SARS-CoV-2, mutations occur naturally when they propagate and spread in human populations. SARS-CoV-2 occurrence accumulates globally at the rate of about one to two mutations per month (COG-UK genetics specialist). Since the virus appeared in 2019, there have also been several thousands of mutations in the SARS-CoV-2 genome[52]. Many mutations have little obvious impact on the virus and which alter the virus at the minority stage, such as making it more capable of infecting individuals and causing serious disease. The mutant virus may be less vulnerable to the immune response mechanism caused by a normal or vaccine[22].As in the flu vaccine, in order to combat new pathogens, the COVID-19 vaccine will still need to be tweaked periodically.

The mapping of the Covid-19 (New strain) samples indicated that the VUI-202012/01 mutations were present[53]. On 19 December 2020 (Saturday), the United Kingdom declared a sudden lockout in London and areas of the world with about 35,000 new infections on the 17th of December, the largest in one day[54]. As of 13 December, a public health announcement from England reported 1108 COVID-19 cases with a new form in south and east England (Thomson Reuter Posted December 15th 2020). Scientists also found 17 improvements to the

essential spike protein of the virus that has developed.A recent strain of SARS-CoV-2 has been discovered to be 70% more contagious than any other strain[55]. The majority of recent events in the UK (approximately 60%) are still thought to be driven by this new variant. The new strains in the UK and South Africa have some fascinating parallels. In these two nations, the health experts say that it seems to be spreading more quickly.

Uniqueness of New Covid strain

First picked up in September, the latest strain named VUI-202012/01 appears to be associated with an outbreak of infections in London and the South East[56]. The above strain is a variant of SARS-CoV-2 that is significantly distinct from the older strains of the virus. The amino acids make up the virus's key components. Modifying one amino acid to another and deleting two other amino acids are the three major mutations. The move is called N501Y and the sections that are omitted are designated His69 and Val70.

Reasons for progress in Vaccinations

Within the body, antibodies will target and kill the current COVID virus[57]. People who once had the virus or a vaccine create and maintain the antibodies, so they will get rid of them before they get infected if the virus comes into their body again. Antibodies exclusively for one virus typically do not work for another virus/strain of the same virus, although this does not appear to be the case yet. A vaccination cannot be used a second time as a result. The effectiveness of the vaccine was only determined in step 3 directions. By educating the immune system, most COVID vaccines work to detect the virus spike proteins and attack them as the virus attempts to infect them in the future.But if the shape of the spike proteins were altered by mutations, there was a risk that the virus would slip through the normal defences of the body. From now on, a few more mutations may occur and continue to affect the vaccine for a year. So the vaccination will have to be modified with various protein antigen coding genes for the next year to match the current strain, so that in the future it will not be an alarming thing.

The COVID vaccine challenges that lie ahead

When positive results do emerge, researchers must help the world conquer vaccine hesitancy, production logistics, and pricing. According to findings published so far, major clinical trials of four vaccine candidates are showing impressive promise, with three reaching 90 percent effectiveness, an unusually high rate. In older adults, a population that is especially vulnerable to SARS-CoV-2 but often reacts less well to vaccinations none registered alarming safety signals and one showed promise. Early experiments found that the immune response could be activated by these candidate vaccines. The new findings indicate that this immune reaction is a significant accomplishment that can defend individuals against COVID-19. The creation of antibodies is overflowing with potential for dissatisfaction, and surprisingly the most excited hopeful person might not have anticipated to have a profoundly effective immunization against another infection not exactly a year in the wake of sequencing its genome. But researchers and physicians also have a tremendous amount of work to do. Second, in populaces who are at high danger of COVID-19, including older grown-ups, individuals with stoutness and those with diabetes, they need to evaluate how well the antibodies function[58]. Second, how effectively any of the vaccines defend against extreme COVID-19 is not clear[59]. Third, it is still not clear to what degree the vaccines avoid the passing of the virus to those among people who have been vaccinated.

COVID vaccine confidence requires radical transparency

Around the same time, experts and decision makers need to understand how to cope with challenges not connected to the applicants for the vaccine themselves. Vaccination apprehension, dissatisfaction with current public-health restrictions, and the challenging logistics of vaccination for the global population are among them. Albeit the end goal is by all accounts in sight, there is still a ton of troublesome territory to survive.

Some individuals are reasonably worried that, considering vaccine inventor' and controllers' affirmations despite what is generally expected, the pace of both clinical evaluation and vaccine regulation could endanger safety. It is crucial that regulators, firms and their testing collaborators keep the commitments they have made to guarantee openness unveil information and participate in open discourse of those information as they show up to make trust in vaccination.

The USFDA pledged to hold a public meeting with its external advisors in early December to review the evidence before authorising a vaccine delivery permit for emergency use. There is a strong need for this kind of accountability and the option of free airing of data issues, should there be any. It stands in contrast to the prior, opaque awarding of COVID-19 care authorizations by the department.

Emergency COVID-19 vaccine approvals pose a dilemma for scientists:

Most vaccine teams and drug regulators have demonstrated their adherence to transparency of results. Yet much of what we hear about the new vaccine trials has been shared through press releases and television reports, rather than through unbiased peer review research papers.

In an emergency, this speed of contact is necessary. However, it is not appropriate to hold back more complete data, and the teams involved must be prepared to have access to all applicable data as quickly as reasonably possible, to allow others to scrutinise their results and verify their statements. It is vital that firms continue to report their knowledge as experiments are conducted, and publish preprint articles of completed trials, so that the study can be addressed easily.

In order to speed up approval decisions around the world, authorities can also exchange their data and findings with regulatory bodies in other countries. And authorities and vaccine producers must note that if individuals reject inoculation due to vaccine hesitancy, vaccinations would be less successful.

It is also important that the existing policies for general wellbeing are not loose. In some nations, the coming festival season could cause episodes as people rush to see since quite a while ago missed family members and companions. Watchfulness is as yet basic, perhaps more along these lines, when individuals at the end of the pandemic tunnel see a welcoming light. The delivery of vaccinations provides another challenging challenge which is followed by questions like how much it will cost and who will pay for it. Various Researchers around worlds are assuming that improved vaccines may be kept in a regular refrigerator, making it more viable for rapid delivery with storage condition below -70 ° C.

Pertinently, AstraZeneca and Oxford have both undertaken to distribute their vaccine at cost to everyone after the pandemic, and to retain this price for low- and middle-income countries after the pandemic, when a vaccine will still be needed in the event of future outbreaks. Still, when Nature went to print, neither Pfizer nor Moderna, a drug manufacturer with an equally ambitious vaccine candidate in Cambridge, Massachusetts, had committed to keeping costs down until the latest pandemic had finished. This stance they need to alter.

COVAX, a global coalition aimed at ensuring an adequate supply of vaccines for low resource setting countries, has only been able to provide vaccines for about 250 million people, far less than what is needed. If interest rates rise, the poorer countries will be much less able to cope than they are now.

It would be morally unethical not to make the vaccine available for these countries. That may also be short-sighted, because, as experts in infectious diseases always claim, an epidemic is an outbreak everywhere.

DISCUSSION

Although the full influence of precession medicine and precession approaches to public health in tackling COVID-19 is too early to be understood, we have argued that "precision" is important to public health activities in a variety of areas, such as recognising individual hazards, encouraging public health monitoring, and enhancing the efficiency of vaccines[36]. We must recognise the potential unintended effects when precision medicine and Public health measures are taken and ensuring that initiatives should not intensify existing inequalities[37]. Precision interventions are promising, but should supplement strategies to improve public health systems and solve the root causes of disease, rather than replacing them. (2021 etal: Amy Zhou)[38]

Companies across the world had to reinvent their activities almost immediately, when COVID-19 triggered profound disruption; through

cultures, how we communicate, how we function, our healthcare structures, our economy [61]. The increasingly evolving climate has become a force for reform as it shaped the adoption and usage of emerging health technology by the global health sector, such as telemedicine, triage (Dtx).

Finally, a massive global initiative and coordination between antibody manufacturers, controllers, campaign makers, funders, general wellbeing bodies, and governments will be required needed to guarantee that promising candidates for final-stage immunizations can be produced in adequate quantities and distributed fairly to any impacted nation, especially low-income areas.

REFERENCES:

1. Larson HJ. Stuck: How Vaccine Rumors Start--and Why They Don't Go Away. Oxford University Press.
2. Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. *Expert Rev. Vaccines*. 8(5), 547–557 (2009).
3. Privor-Dumm LA, Poland GA, Barratt J, *et al.* A global agenda for older adult immunization in the COVID-19 era: a roadmap for action. *Vaccine*. (2020).
4. Penney CA, Thomas DR, Deen SS, Walmsley AM. Plant-made vaccines in support of the Millennium Development Goals. *Plant Cell Rep.* 30(5), 789–798 (2011).
5. Zhu F-C, Li Y-H, Guan X-H, *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet*. 395(10240), 1845–1854 (2020).
6. Organization WH. Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization. (2016).
7. Han S, Roy PK, Hossain I, Byun K-H, Choi C, Ha S-D. COVID-19 pandemic crisis and food safety: Implications and inactivation strategies. *Trends Food Sci. Technol.* (2021).
8. Kristensen D, Chen D, Cummings R. Vaccine stabilization: research, commercialization, and potential impact. *Vaccine*. 29(41), 7122–7124 (2011).
9. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. *Nat. Biotechnol.* 28(6), 573–579 (2010).
10. Lee BY, Norman BA, Assi T-M, *et al.* Single versus multi-dose vaccine vials: an economic computational model. *Vaccine*. 28(32), 5292–5300 (2010).
11. Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. *Biologicals*. 42(5), 237–259 (2014).
12. Lloyd J, Cheyne J. The origins of the vaccine cold chain and a glimpse of the future. *Vaccine*. 35(17), 2115–2120 (2017).
13. Woodle D. Vaccine procurement and self-sufficiency in developing countries. *Health Policy Plan.* 15(2), 121–129 (2000).
14. Blue JT, Sinacola JR, Bhambhani A. Process scale-up and optimization of lyophilized vaccine products. In: *Lyophilized Biologics and Vaccines*, Springer, 179–210 (2015).
15. Yaqub O. Testing regimes in clinical trials: Evidence from four polio vaccine trajectories. *Res. Policy*. 46(2), 475–484 (2017).
16. Kumar P. Structure and Performance of Food Processing Industry in India. *J. Indian Sch. Polit. Econ.* 22(1–4), 127–163 (2010).
17. Comes T, Sandvik KB, Van de Walle B. Cold chains, interrupted: The use of technology and information for decisions that keep humanitarian vaccines cool. *J. Humanit. Logist. Supply Chain Manag.* (2018).
18. Kumar R, Ghosh M, Kumar S, Prasad M. Single cell metabolomics: a future tool to unmask cellular heterogeneity and virus-host interaction in context of emerging viral diseases. *Front. Microbiol.* 11, 1152 (2020).
19. Al-Kassmy J, Pedersen J, Kobinger G. Vaccine candidates against Coronavirus infections. Where Does COVID-19 stand? *Viruses*. 12(8), 861 (2020).
20. Yang Y, Li H, Li Z, *et al.* Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens. *Vaccine*. 33(9), 1143–1150 (2015).
21. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. *Nat. Rev. Immunol.* 20(10), 615–632 (2020).
22. Cox RJ, Brokstad KA, Ogra PL. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. *Scand. J. Immunol.* 59(1), 1–15 (2004).
23. Kabytaev K, Durairaj A, Shin D, *et al.* Two‐step ion‐exchange chromatographic purification combined with reversed‐phase chromatography to isolate C‐peptide for mass spectrometric analysis. *J. Sep. Sci.* 39(4), 676–681 (2016).
24. Nascimento IP, Leite LCC. Recombinant vaccines and the development of new vaccine strategies. *Brazilian J. Med. Biol. Res.* 45(12), 1102–1111 (2012).
25. Qu W, Wang M, Wu Y, Xu R. Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties. *Curr. Pharm. Biotechnol.* 16(8), 684–695 (2015).
26. Asensio MA, Morella NM, Jakobson CM, *et al.* A selection for assembly reveals that a single amino acid mutant of the bacteriophage MS2 coat protein forms a smaller virus-like particle. *Nano Lett.* 16(9), 5944–5950 (2016).
27. Park C-H, Chen S, Shirsekar G, *et al.* The Magnaporthe oryzae effector AvrPiz-t targets the RING E3 Ubiquitin Ligase APIP6 to suppress pathogen-associated molecular pattern–triggered immunity in rice. *Plant Cell*. 24(11), 4748–4762 (2012).
28. Abdulrahman A, Ghanem A. Recent advances in chromatographic purification of plasmid DNA for gene therapy and DNA vaccines: a review. *Anal. Chim. Acta*. 1025, 41–57 (2018).
29. Lancaster C, Pristatsky P, Hoang VM, *et al.* Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP. *J. Chromatogr. B*. 1032, 218–223 (2016).
30. Rohovie MJ, Nagasawa M, Swartz JR. Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery. *Bioeng. Transl. Med.* 2(1), 43–57 (2017).
31. Verez-Bencomo V, Fernandez-Santana V, Hardy E, *et al.* A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. *Science (80-.).*305(5683), 522–525 (2004).
32. Van Bavel JJ, Baicker K, Boggio PS, *et al.* Using social and behavioural science to support COVID-19 pandemic response. *Nat. Hum. Behav.* 4(5), 460–471 (2020).
33. Laurencin CT, McClinton A. The COVID-19 pandemic: a call to action to identify and address racial and ethnic disparities. *J. racial Ethn. Heal. disparities*. 7(3), 398–402 (2020).
34. Lin C, Tu P, Beitsch LM. Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. *Vaccines*. 9(1), 16 (2021).
35. Bol D, Giani M, Blais A, Loewen PJ. The effect of COVID‐19 lockdowns on political support: Some good news for democracy? *Eur. J. Polit. Res.* (2020).
36. Cavallo JJ, Donoho DA, Forman HP. Hospital capacity and operations in the coronavirus disease 2019 (COVID-19) pandemic—planning for the nth patient. In: *JAMA Health Forum*, American Medical Association, e200345–e200345 (2020).
37. Ogunleye OO, Basu D, Mueller D, *et al.* Response to the novel corona virus (COVID-19) pandemic across Africa: successes, challenges, and implications for the future. *Front. Pharmacol.* 11, 1205 (2020).
38. Zhou A, Sabatello M, Eyal G, *et al.* Is precision medicine relevant in the age of COVID-19? *Genet. Med.* , 1–2 (2021).
39. Wang J, Peng Y, Xu H, Cui Z, Williams RO. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. *AAPS PharmSciTech*. 21(6), 1–12 (2020).
40. Denys A, Guiu B, Chevallier P, Digklia A, de Kerviler E, De Baere T. Interventional oncology at the time of COVID-19 pandemic: problems and solutions. *Diagn. Interv. Imaging*. 101(6), 347–353 (2020).
41. Le TT, Andreadakis Z, Kumar A, *et al.* The COVID-19 vaccine development landscape. *Nat Rev Drug Discov*. 19(5), 305–306 (2020).
42. Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. mRNA-based dendritic cell vaccines. *Expert Rev. Vaccines*. 14(2), 161–176 (2015).
43. Nichol AA. Potential implications of testing an experimental mRNA-based vaccine during an emerging infectious disease pandemic. *Am. J. Bioeth.* 20(7), W2–W3 (2020).
44. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. *Vaccines*. 2(3), 624–641 (2014).
45. Cox MMJ. Recombinant protein vaccines produced in insect cells. *Vaccine*. 30(10), 1759–1766 (2012).
46. Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. *Nat. Biotechnol.* 38(7), 789–791 (2020).
47. Lambert P-H, Ambrosino DM, Andersen SR, *et al.* Consensus summary report for CEPI/BC March 12–13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines. *Vaccine*. 38(31), 4783–4791 (2020).
48. Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. *Life Sci.* , 117956 (2020).
49. Lucas S, Nelson AM. HIV and the spectrum of human disease. *J. Pathol.* 235(2), 229–241 (2015).
50. Parker J. Variations in reading the genetic code. *Transf. RNA protein Synth.* , 191–267 (1992).
51. Zhai X, Sun J, Yan Z, *et al.* Comparison of SARS-CoV-2 spike protein binding to ACE2 receptors from human, pets, farm animals, and putative intermediate hosts. *J. Virol.* (2020).
52. Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. *Front. Microbiol.* 11, 1800 (2020).
53. Golubchik T, Lythgoe KA, Hall MD, *et al.* Early Analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. *medRxiv*. (2021).
54. Raoofi A, Takian A, Sari AA, Olyaeemanesh A, Haghighi H, Aarabi M. COVID-19 pandemic and comparative health policy learning in Iran. *Arch. Iran. Med.* 23(4), 220–234 (2020).
55. Islam MR, Hoque MN, Rahman MS, *et al.* Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity. *Sci. Rep.* 10(1), 1–9 (2020).
56. de Cosio FG, Diaz-Apodaca B, Cesar Sandate PGY. The United Kingdom's new variant of COVID-19: what we know and what we don't know, and what we can do to respond to this challenge. (2021).
57. Liu C, Zhou Q, Li Y, *et al.* Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. (2020).
58. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19). *Diabetes. Metab. Res. Rev.* 37(2), e3377 (2021).
59. Shi Y, Wang Y, Shao C, *et al.* COVID-19 infection: the perspectives on immune responses. (2020).
60. Hanney SR, Wooding S, Sussex J, Grant J. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons? *Heal. Res. policy Syst.* 18, 1–10 (2020).
61. Buheji M, Ahmed D. Foresight of Coronavirus (COVID-19) opportunities for a better world. *Am. J. Econ.* 10(2), 97–108 (2020).